Prelude Therapeutics (PRLD) EBIT Growth (3y) (2022 - 2026)

Prelude Therapeutics (PRLD) EBIT Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Prelude Therapeutics 324.30 Mn 179.71 Mn - 21.33%

Historic Data

Download Data
DateValue
Mar 31, 2026 21.33%
Dec 31, 2025 19.60%
Sep 30, 2025 12.43%
Jun 30, 2025 -3.00%
Mar 31, 2025 -4.54%
Dec 31, 2024 -0.82%
Sep 30, 2024 -3.69%
Jun 30, 2024 -10.00%
Mar 31, 2024 -16.06%
Dec 31, 2023 -24.34%
Sep 30, 2023 -22.54%
Jun 30, 2023 -41.50%
Mar 31, 2023 -44.07%
Dec 31, 2022 -48.99%
Sep 30, 2022 -64.07%